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Abstract
Background: β2-Adrenergic receptors (β2AR) play important regulatory roles in a variety of cells
and organ systems and are important therapeutic targets in the treatment of airway and
cardiovascular disease. Prolonged use of β-agonists results in tolerance secondary to receptor
down-regulation resulting in reduced therapeutic efficiency. The purpose of this work is to evaluate
the signaling capabilities of the β2AR expressed by a recombinant adeno-associated viral (AAV)
vector that also included an enhanced green fluorescent protein (EGFP) gene (AAV-β2AR/EGFP).
Results: By epifluorescence microscopy, ~40% of infected HEK 293 cells demonstrated EGFP
expression. β2AR density measured with [3H]dihydroalprenolol ([3H]DHA) increased either 13- or
77-fold in infected cells compared to mock infected controls depending on the culture conditions
used. The [3H]DHA binding was to a single receptor population with a dissociation constant of 0.42
nM, as would be expected for wild-type β2AR. Agonist competition assays with [3H]DHA showed
the following rank order of potency: isoproterenol>epinephrine> norepinephrine, consistent with
β2AR interaction. Isoproterenol-stimulated cyclic AMP levels were 5-fold higher in infected cells
compared to controls (314 ± 43 vs. 63.4 ± 9.6 nmol/dish; n = 3). Receptor trafficking demonstrated
surface expression of β2AR with vehicle treatment and internalization following isoproterenol
treatment.
Conclusions: We conclude that HEK 293 cells infected with AAV-β2AR/EGFP effectively express
β2AR and that increased expression of these receptors results in enhanced β2AR signaling. This
method of gene transfer may provide an important means to enhance function in in vivo systems.
Background
The β2-adrenergic receptor (β2AR) is a member of the gua-
nine nucleotide regulatory protein (G-protein) coupled
receptor superfamily that mediates the effects of the cate-
cholamines epinephrine and norepinephrine. β2ARs are
widely expressed in a variety of tissues including the
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airways of the lung and the cardiovascular system. β2ARs
mediate airway smooth muscle relaxation, increase ciliary
motility, improve ion transport across epithelium, and
reduce inflammatory cell mediator release. In the cardio-
vascular system, β2ARs regulate vascular tone and enhance
chronotropic effects on cardiac muscle [1,2].
Investigators have previously used viral gene transfer and
transgenic animal models to demonstrate that physio-
logic responsiveness to catecholamines can be enhanced
by increasing β2AR expression. Over-expression of β2AR
has been shown to have beneficial effects in the failing
heart. Transgenic over-expression of β2AR and β-adrener-
gic receptor kinase 1 (βARK1) inhibitor in cardiac muscle
results in improvement in cardiac contractile function
caused by changes in β2AR activation and signaling [3,4].
Adenoviral-mediated gene transfer of β2AR to failing rab-
bit cardiac myocytes [5] and ex vivo to adult rat hearts [6]
results in restoration of β2AR signaling in cardiac muscle.
Likewise, adenoviral-mediated β2AR gene delivery to rat
carotid arteries leads to enhanced vasorelaxation in
response to isoproterenol when compared to control ani-
mals [7].
Transgenic over-expression of β2AR in airway smooth
muscle using a smooth muscle-specific promoter is asso-
ciated with protection against methacholine-induced
bronchoconstriction [8]. Similarly, targeted over-expres-
sion of β2AR in mouse airway epithelium using a Clara
cell-specific promoter results in reduced airway respon-
siveness to both methacholine and ozone [9]. These data
in airway epithelium confirmed the importance of airway
relaxation mediated through airway epithelial β2AR [10].
Transgenic over-expression of β2AR in type II alveolar cells
results in enhanced alveolar fluid clearance [11]. Further-
more, adenoviral-mediated over-expression of β2AR in
human lung epithelial cells (A549) is associated with
enhanced fluid clearance and responsiveness to endog-
enous catecholamines [12].
The application of β2AR gene transfer to a variety of cell
types is especially appealing in light of the myriad of
important physiological functions of β2AR. The strategy of
our work is to develop a useful gene delivery model for
increased expression of the β2AR utilizing an adeno-asso-
ciated viral (AAV) vector. While other viral vectors have
proven useful in β2AR gene transfer in animal models, we
have chosen to use AAV due to its long term potential as a
gene delivery system for use in humans. We have devel-
oped a recombinant AAV containing the β2AR and
enhanced green fluorescent protein (EGFP). The purpose
of this study is to evaluate the signaling capabilities of the
expressed β2AR. Our findings demonstrate that expression
of β2AR can be significantly increased in infected cells and
that the expressed receptors serve to enhance physiologic
responsiveness to adrenergic agonists.
Results
Efficiency of gene delivery in HEK 293 cells
A recombinant adeno-associated viral (rAAV) vector was
designed to include tandem cassettes encoding the human
β2AR and enhanced green fluorescent protein (EGFP)
genes and was designated AAV-β2AR/EGFP (Figure 1). To
evaluate for efficiency of viral unit transfer into AAV-
β2AR/EGFP infected cells, the detection of EGFP was used
as a surrogate or screening marker for β2AR expression.
HEK 293 cells were visualized using epifluorescence
microscopy. Approximately 40% of cells infected with
AAV-β2AR/EGFP (200 transducing units/cell) demon-
strated green fluorescence (Figure 2), while mock infected
cells lacked EGFP expression (data not shown). These
results indicate that HEK 293 cells are readily infected
with a recombinant AAV and that the EGFP cassette was
expressed.
Pharmacologic specificity of recombinant β2-adrenergic 
receptors
To determine the pharmacologic characteristics of the
recombinant β2AR, we used HEK 293 cells because of their
low endogenous expression of β2AR. We first sought to
determine the characteristics of the expressed receptor in
saturation binding experiments. [3H]dihydroalprenolol
([3H]DHA) binding to membranes prepared from AAV-
β2AR/EGFP-infected HEK 293 cells was to a single, satura-
ble site that displayed high affinity as shown in a repre-
sentative Scatchard plot (Figure 3). Separate experiments
with four different membrane preparations established a
binding site concentration (Bmax) of 5.05 ± 1.0 pmol/mg
protein (n = 4) and a dissociation constant (Kd) of 0.42 ±
0.1 nM (n = 4). These findings demonstrate [3H]DHA
binding to a single population of receptors with affinity
expected for wild-type β2AR [13].
The specificity of [3H]DHA binding was examined in com-
petition binding assays using various adrenergic agonists
(Figure 4). In five separate experiments, the rank order
potency of agonist binding to membranes prepared from
HEK 293 cells infected with AAV-β2AR/EGFP was isoprot-
erenol (Ki = 1.9 ± 0.7 µM) > epinephrine (Ki = 5.7 ± 2.5
µM) > norepinehrine (Ki = 22.8 ± 7.7 µM) (n = 5). This
rank order potency is consistent with a β2AR interaction.
Increased β2AR expression in AAV-β2AR/EGFP infected 
HEK 293 cells
HEK 293 cells express low levels of β2AR [14]. To deter-
mine the capability of AAV-β2AR/EGFP to increase β2AR
expression in HEK 293 cells, ligand binding assays were
employed in AAV-β2AR/EGFP infected and mock-infected
cells grown in DMEM supplemented with 10% FBS. MockBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/15
Page 3 of 12
(page number not for citation purposes)
infected HEK 293 cells demonstrated specific binding of
[3H]DHA to a single saturable site at a level of 39 ± 11
fmol/106 cells. β2AR levels were significantly (p < 0.001)
increased in AAV-β2AR/EGFP infected cells to 501 ± 82
fmol/106 cells, representing a 13-fold increase in β2AR
expression levels when comparing AAV-β2AR/EGFP
infected cells to mock-infected cells (Figure 5). To further
assess the role of serum source on β2AR expression in
infected HEK 293 cells, we conducted similar studies
using 5% CS. In cells cultured in DMEM with 5% CS,
background  β2AR expression was lower than in cells
grown in 10% FBS, with mock-infected cells showing
β2AR levels of 5.5 ± 3.4 fmol/106 cells. β2AR levels were
significantly increased (p < 0.001) in AAV-β2AR/EGFP
infected cells to 428 ± 95 fmol/106 cells, representing a 77-
fold increase in β2AR levels when comparing AAV-β2AR/
EGFP infected cells to mock-infected cells grown in 5% CS
(Figure 5). This dramatic increase in receptor expression
when comparing cells grown in 5% CS to those grown in
10% FBS was due to differences in baseline β2AR expres-
sion in mock-infected cells. Interestingly, the absolute
level of β2AR expression after AAV-β2AR/EGFP infection
was not different between culture conditions. Overall,
these results indicate that β2AR levels can be significantly
increased in HEK293 cells infected with AAV-β2AR/EGFP,
but that there may be an upper limit for membrane
expression of β2AR in this cell line.
Recombinant AAV structures Figure 1
Recombinant AAV structures. A. In wild-type AAV, the rep region encodes products required for AAV DNA replication. The 
lip and cap regions encode the virion capsid proteins. The internal terminal repeats (ITR) are required in cis for AAV packaging 
and integration into host DNA. B. AAV-β2AR/EGFP represents the complete recombinant vector with tandem β2AR and EGFP 
cassettes driven by separate CMV promoters.
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Enhanced cAMP signaling in infected HEK 293 cells
Binding of agonist to the β2AR results in adenylyl cyclase
activation and conversion of ATP to cyclic AMP [15]. To
evaluate the ability of the recombinant β2AR to activate
early receptor signaling pathways, isoproterenol-stimu-
lated cyclic AMP accumulation was measured in HEK 293
cells infected with AAV-β2AR/EGFP (Figure 6). Cells were
treated with the phosphodiesterase inhibitor, IBMX, at the
time of isoproterenol treatment to maximize the cyclic
AMP signal. In mock-infected (control) cells, cyclic AMP
accumulation was 4.83 ± 0.42 nmoles/dish in the absence
of isoproterenol and 63.4 ± 9.6 nmoles/dish in the pres-
ence of isoproterenol, representing a 13-fold increase in
cyclic AMP accumulation in isoproterenol-treated, mock
infected cells. In AAV-β2AR/EGFP infected cells, cyclic
AMP accumulation increased from 4.69 ± 0.84 nmoles/
dish in the absence of isoproterenol stimulation to 314 ±
43 nmoles/dish in the presence of isoproterenol, repre-
senting a 67 fold increase in cyclic AMP accumulation.
The increase in cyclic AMP production in AAV-β2AR/EGFP
infected cells was significantly different from control,
mock infected cells (p < 0.05). These data indicate that in
addition to binding agonists with the expected pharmaco-
logic specificity, the recombinant β2AR was capable of
interacting with downstream intracellular signaling pro-
teins to stimulate cyclic AMP accumulation.
Analysis of EGFP expression in infected HEK 293 cells Figure 2
Analysis of EGFP expression in infected HEK 293 cells. Cells were cultured in 10% FBS and were infected with AAV-β2AR/
EGFP and screened for EGFP expression as a surrogate marker of β2AR expression efficiency. Using epifluorescence micros-
copy to compare phase contrast (A) and green fluorescence (B), EGFP expression was observed in ~40% of cells present, as 
seen in this representative image. This experiment was performed 5 times with similar results. Scale bar, 10 µM.
A BBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/15
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Intracellular trafficking of recombinant β2AR in infected 
HEK 293 cells
Previous reports indicate that ligand-induced trafficking
of the β2AR begins in the early endosome [14,16].
Through further intracellular signaling, the internalized
β2AR is then either recycled to the plasma membrane or is
committed to a degradation pathway terminating in the
lysosome [17]. To determine if the recombinant β2AR
expressed from AAV-β2AR/EFGP retains receptor traffick-
ing in HEK 293 cells, receptor distribution was assessed
using a polyclonal antibody to the cytoplasmic tail of the
β2AR labeled with a Texas Red fluorochrome. Recom-
binant receptors were localized to the cell surface after
treatment with vehicle alone, with minimal evidence for
intracellular distribution (Figures 7, Panel A). Following
isoproterenol treatment for 20 minutes, recombinant
β2AR were observed to move from the cell surface to
small, punctate intracellular vesicles with minimal surface
expression noted (Figure 7, Panel B). Following isoproter-
enol treatment for 24 hours, recombinant β2AR were
noted to traffick to both large and small, perinuclear vesi-
cles as would be expected for wild-type receptors follow-
ing prolonged agonist exposure (Figure 7, Panel C).
Additionally, images obtained after 24 hour agonist treat-
ment suggest that some receptors were located on the
plasma membrane possibly due to efficient recycling
mechanisms as is seen with native β2AR [18] or due to the
abundance of expressed β2AR. These results indicate that
agonist induced trafficking of recombinant β2AR remains
intact with ligand-induced internalization of receptor but
Saturation binding of [3H]DHA to membranes prepared from HEK 293 cells cultured in 10% FBS and infected with AAV-β2AR/ EGFP Figure 3
Saturation binding of [3H]DHA to membranes prepared from HEK 293 cells cultured in 10% FBS and infected with AAV-β2AR/
EGFP. Membranes were incubated at 30°C for 20 minutes with increasing concentrations of [3H]DHA. Non-specific binding 
was defined with 0.1 µM (-)-propranolol. Inset: Direct plot showing total binding (closed circles), nonspecific binding (closed tri-
angles), and specific binding (open circles). These data were representative of four separate experiments.
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with retention of some cell surface expression, even after
prolonged agonist exposure. These results further suggest
that an added benefit of recombinant β2AR expression is
persistence of β2AR on the cell surface in the continuing
presence of agonist.
Discussion
In this study, we have developed and tested a model for
the delivery of the genes encoding the β2AR and enhanced
green fluorescent protein to cultured cells. We have dem-
onstrated that utilization of a recombinant AAV vector
provides an effective means of gene delivery without evi-
dence of cell toxicity four days after infection. We have
also shown that expressed recombinant β2AR have phar-
macologic and functional properties characteristic of wild
type β2AR but with enhanced expression and signaling.
These findings provide a new model for the study of β2AR
expression in tissue that is efficient and serves as a
framework for study in physiologically relevant tissue (e.g,
airway cells or lung tissue).
The role of gene transfer in the treatment of disease is
evolving and shows promise in many disorders [19].
Transfer of the β2AR gene to cardiac, vascular, and airway
epithelial tissue has been accomplished using adenoviral
vectors [6,7,12]. Similarly, adenoviral-mediated transfer
of the β-adrenergic receptor kinase 1 (βARK1) inhibitor
gene, important in controlling β2AR activation and signal-
ing, has been performed in cardiac myocytes [5].
Enhanced expression of β2AR or signaling pathway
Adrenergic agonist competition with [3H]DHA binding to membranes prepared from HEK293 cells cultured in 10% FBS that  had been infected with AAV-β2AR/EGFP Figure 4
Adrenergic agonist competition with [3H]DHA binding to membranes prepared from HEK293 cells cultured in 10% FBS that 
had been infected with AAV-β2AR/EGFP. Membranes were incubated at 30°C for 20 minutes with [3H]DHA and increasing 
concentrations of either (-)-isoproterenol (circles), (-)-epinephrine (squares), or (-)-norepinephrine (triangles). These data 
were representative of four separate experiments.
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components in cardiac tissue has resulted in improve-
ments in cardiac function [20], while over-expression of
β2AR in vasculature results in enhanced vasorelaxation
[7]. Similarly, adenoviral-mediated transfer of the β2AR
gene to airway epithelium improved fluid clearance and
response to catecholamines [12]. For β2AR gene delivery,
we have chosen to utilize an adeno-associated viral vector.
The AAV system provides several advantages over other
viral vectors including: 1) its ability to transduce both
dividing and non-dividing cells; 2) its broad tropism; 3)
its ability to integrate into the host genome; 4) its status as
a nonpathogenic virus; and 5) its lack of induction of a
cell-mediated immune response [21]. One important lim-
itation to the use of AAV vectors for gene transfer is the
size constraint in gene packaging, limited to 4.7 kb, the
size of the AAV genome. Because the β2AR is a relatively
small, intronless gene it is well-suited for AAV vector
delivery. Our system is the first to use AAV to enhance
β2AR expression thus providing a model that has applica-
bility toward our ultimate target, human disease.
Our investigation has focused at present on both the
development of an efficient recombinant AAV system to
deliver the β2AR gene to cultured cells and functional
testing to determine that the β2AR expressed following
infection of HEK 293 cells with AAV-β2AR/EGFP has prop-
erties characteristic of wild-type β2AR but with the ability
to significantly enhance signaling and impart improved
responsiveness to hormone. HEK 293 cells were chosen
for study because of their ease of culture, low endogenous
β2AR expression in infected vs. control HEK 293 cells Figure 5
β2AR expression in infected vs. control HEK 293 cells. HEK 293 cells were cultured in DMEM with either 5% CS or 10% FBS 
then either mock infected (control) or infected with AAV-β2AR/EGFP. Cells were harvested and incubated at 30°C for 20 min-
utes with a saturating concentration of [3H]DHA to determine β2AR levels as described in Methods. Non-specific binding was 
defined with 0.1 µM (-)-propranolol. Values are the means ± S.E. from five different experiments.
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β2AR expression, and prior utility in other studies of β2AR
function [14]. Four days after infection, up to 40% of
infected cells expressed EGFP, and β2AR levels were
increased significantly compared to mock infected cells.
Cells cultured in 10% FBS demonstrated a 13-fold
increase in receptor expression, while those cultured in
5% CS demonstrated a 77-fold increase. This difference
was due to higher receptor expression in mock-infected
(control) cells when cultured in 10% FBS with the abso-
lute level of receptor expression being equivalent despite
growth media conditions. Ligand binding studies demon-
strated that recombinant β2AR represented a single popu-
lation of receptors with pharmacological properties that
were identical to wild-type β2AR. These studies also sug-
gest that an upper limit for membrane expression of
recombinant receptors may have been reached in HEK
293 cells.
It has been long recognized that epinephrine and nore-
pinephrine acting through β2AR modulate a variety of
important cellular and tissue functions [1]. Although
these effects may be beneficial to the host, prolonged use
of agonist agents has been associated with detrimental
effects through the well-known phenomenon of
tachyphylaxis or tolerance [22,23]. Tachyphylaxis results
from a culmination of molecular events including recep-
tor desensitization, sequestration and down-regulation
[24]. Thus, we have asked an important, physiologically
relevant question. Can over-expression of β2AR using an
AAV-mediated delivery system reduce β2AR
Isoproterenol-stimulated cyclic AMP production in HEK 293 cells cultured in 10% FBS and infected with AAV-β2AR/EGFP Figure 6
Isoproterenol-stimulated cyclic AMP production in HEK 293 cells cultured in 10% FBS and infected with AAV-β2AR/EGFP. 
HEK 293 cells were either mock infected (control) or infected with AAV-β2AR/EGFP. Four days later, the cells were incubated 
with 250 µM IBMX and either 10 µM (-)-isoproterenol or vehicle for 15 min at 37°C, and cyclic AMP was measured as 
described in Materials and Methods. Values are the means ± S.E. from three separate experiments.
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tachyphylaxis? We hypothesized that this could occur
through three possible mechanisms: 1) through addition
of increased numbers of β2AR to the cell, 2) through
enhanced recycling, and/or 3) through reduced receptor
down-regulation.
The use of fluorescent microscopy to monitor trafficking
of receptors in cells can provide further insight related to
the fate of the β2AR following agonist activation. In stable
transfection models, β2AR have been shown to sequester
to the intracellular environment within minutes after ago-
nist activation and co-localize with transferrin-containing
compartments, characteristic of recycling endosomes
[14,17]. Using a β2AR-GFP fusion gene, Kallal and Ben-
ovic demonstrated that with prolonged agonist treatment,
β2AR co-localize with dextran-labeled compartments,
characteristic of lysosomes [17]. Our initial studies con-
firm that recombinant β2ARs localize to the plasma mem-
brane prior to agonist treatment and efficiently sequester
to intracellular vesicles following agonist treatment. Our
findings also indicate persistence of receptor expression
on the cell surface following ligand-induced activation
and intracellular trafficking. Persistence of surface expres-
sion may provide a physiologic advantage for the cell or
tissue by supplying addition receptors for ligand binding.
Analysis of β2AR trafficking in AAV-β2AR/EGFP infected HEK 293 cells Figure 7
Analysis of β2AR trafficking in AAV-β2AR/EGFP infected HEK 293 cells. Cells were cultured in 10% FBS and treated with either 
vehicle (A), 10 µM isoproterenol for 20 minutes (B) or 10 µM isoproterenol for 24 hr (C) and analyzed via epifluorescence 
microscopy using polyclonal antibody to the cytoplasmic tail of β2AR. Mock infected HEK 293 cells demonstrated no β2AR 
staining (data not shown). Recombinant β2AR showed predominantly surface staining in the presence of vehicle (A). Following 
20 minute isoproterenol treatment, recombinant β2AR were sequestered internally (B). Following 24 hour isoproterenol treat-
ment, recombinant β2AR demonstrated trafficking to large, perinuclear vesicles with some β2AR demonstrated on the surface 
(C). This experiment was performed 3 times with identical results. Scale bar, 10 µM.
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Adeno-associated viral vector mediated gene transfer has
been successful in human trials [19,21] and is the subject
of ongoing research. Genes delivered by AAV vectors
include factor IX and factor VIII for hemophilia, the cystic
fibrosis transmembrane reductance regulator (CFTR) for
cystic fibrosis, and glial cell line-derived neurotrophic fac-
tor (GDNF) and glutamic acid decarboxylase for Parkin-
son's disease. The ability to efficiently deliver β2AR to
airway tissue has the potential to enhance bronchodila-
tion, improve fluid and ion transport and reduce airway
inflammation. These functions may have particular rele-
vance in diseases of airway hyperresponsiveness such as
asthma or chronic obstructive pulmonary disease. Trans-
fer of the β2AR gene to cardiac muscle and the vasculature
can improve chronotropic function, reduce dilation and
enhance vasorelaxation [5-7,20]. For relevance in thera-
peutic delivery for humans, studies related to long-term
gene expression, episomal expression or DNA integration,
and potential adverse effects must be addressed.
Conclusions
In summary, this study has demonstrated that β2AR
expressed in HEK 293 cells infected with AAV-β2AR/EGFP
demonstrate enhanced expression and signaling. This sys-
tem provides a useful, well-characterized model for future
study of β2AR regulation and function. Future studies uti-
lizing AAV-β2AR/GFP should include in vitro studies
assessing the destiny of endogenous receptors in cells
infected with recombinant AAV-β2AR/EGFP. These studies
should be conducted in physiologically relevant cell types
such as airway smooth muscle or epithelium. Using AAV
to enhance β2AR delivery and signaling should also be
studied in animal models of airway hyperresponsiveness
to assess the physiologic impact of AAV vector mediated
β2AR over-expression.
Methods
Recombinant AAV preparation
A recombinant adeno-associated viral (rAAV) vector was
designed to include tandem cassettes encoding the human
β2AR and enhanced green fluorescent protein (EGFP)
genes and was designated AAV-β2AR/EGFP (Figure 1).
Cassettes containing the β2AR and EFGP genes, both
driven by CMV promoters, were cloned into pAV53-LR, a
plasmid vector containing the internal terminal repeats
(ITRs) from AAV (provided by Dr. Juinyan Dong, Medical
University of South Carolina, Charleston, SC). Briefly, the
β2AR gene was PCR-amplified from human genomic DNA
using a forward primer (5'CATATAAAGCTT-
CAGCCAGTGCGCTTACCTGC3') engineered with a Hin-
dIII site (underlined) upstream of the ATG, and a reverse
primer
(5'CATATAGGATCCGTTTAGTGTTCTGTTGGGCGG3')
engineered with a BamHI site (underlined) downstream
of the stop codon. The PCR fragment was subcloned into
pCEP4 vector (Invitrogen, Carlsbad, CA) using HindIII
and BamHI sites. The pCEP4 vector provided the CMV
promoter and SV40 polyA tail adenlyation signal. The
β2AR moiety was released with SalI and subcloned into
the XhoI site of pAV53-LR. To track infection levels using
a surrogate marker gene, the EGFP gene cassette was
inserted into the AAV-β2AR vector. The EGFP gene was
obtained from PCR amplification of pEGFP-C1 plasmid
(Clontech) using a forward primer (5'CATATAGCAT-
GCCCGTATTACCGCCATG-CATTAG3') and a reverse
primer (5'CATATAGCATGCGCCGATTTCGGCCTATTGG-
TTA3') both engineered with SphI sites (underlined). The
EGFP insert was subcloned into the multiple cloning site
of the AAV-β2AR vector using the SphI site. The final
recombinant vector, designated AAV-β2AR/EGFP, has a
total length of 4,691 base pairs encoding the β2AR and
EGFP genes both driven by separate CMV promoters and
containing separate polyadenylation signal sequences.
Cassette orientation and sequence were determined using
automated DNA sequencing. The AAV-β2AR /EGFP vector
was sent to the University of North Carolina Virus Vector
Core Facility (Chapel Hill, NC) for viral production. Stock
preparations used in experiments ranged from 1.0–3.5 ×
1010 transducing units/ml.
Cell culture and infection
The human embryonic kidney cell line, HEK 293, was
used for all experiments. HEK 293 cells were grown in
DMEM supplemented with 10% fetal bovine (FBS). Sup-
plemental studies assessing the role of growth media on
receptor expression were conducted using 5% calf serum
(CS) in place of FBS. HEK 293 cells at a cell density of 0.25
× 106 cells/well in 6 well plates were transduced by addi-
tion of AAV-β2AR/EGFP (200 transducing units/cell in 1
ml of media per well). Approximately 16 hrs after initial
viral application, 1 ml of growth media was added to each
well. Assays to determine β2AR expression levels and func-
tion were performed on day 4 following infection.
Ligand binding assays to determine receptor specificity
Partially purified membrane preparations were obtained
from AAV-β2AR/EGFP infected HEK 293 cells, cultured in
DMEM with 10% FBS, by differential centrifugation as
previously described [13]. Briefly, cells were washed with
ice-cold phosphate-buffered saline (PBS) and scraped into
ice-cold PBS with a rubber policeman. The cells were cen-
trifuged at 250 × g for 5 minutes, resuspended in assay
buffer (50 mM pH 7.4 Tris-HCl, 2 mM MgCl2) and
homogenized with a glass-glass homogenizer followed by
sonication (5–10 second bursts at setting 6) with a Tek-
mar Model AS1 Sonic Disrupter. The nuclei were removed
by centifugation at 600 × g for 10 minutes. Membranes
were obtained from the resulting supernatant by centrifu-
gation at 30,000 × g for 15 minutes, then resuspended in
assay buffer and centrifuged again. The final pellets wereBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/15
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resuspended in assay buffer, aliquoted, and stored at -
80°C. Protein concentrations of membrane preparations
were determined by the method of Bradford [25] using
bovine serum albumin as the standard. [3H]Dihydroal-
prenolol (DHA) (Dupont-NEN, Boston, MA; specific
activity = 120 Ci/mmole) was used to identify β2AR as pre-
viously described [13]. In saturation experiments, aliq-
uots of HEK 293 cell membranes (final concentration in
assay tube = 70 µg/ml) were incubated with 7 different
concentrations of [3H]DHA ranging from approximately
0.05 to 5 nM. In competition experiments, membrane
aliquots were incubated with approximately 1 nM
[3H]DHA and increasing concentrations of the competi-
tors isoproterenol, epinephrine, and norepinehrine
(range 10-9 to 10-4 moles/liter). Nonspecific binding was
defined with 0.1 µM (-)-propranolol. Data from satura-
tion experiments were analyzed using LIGAND [26]. Inhi-
bition constants were calculated using the method of
Cheng and Prusoff [27].
Ligand binding assays to establish the effects of β-agonists 
on β2AR expression
The effects of β-agonist treatment on β2AR expression
were determined by growing AAV-β2AR/EGFP infected
HEK 293 cells in DMEM containing 10% FBS. To deter-
mine the impact of a less enriched media on β2AR expres-
sion, infected HEK 293 cells were also cultured in DMEM
with 5% CS. [3H]DHA was used in ligand binding assays
to determine β2AR levels as previously described [13].
Approximately 1.2 × 106 cells/ml were incubated in tripli-
cate with a single saturating concentration of [3H]DHA
(~5 nM). Nonspecific binding was defined with 0.1 µM (-
)-propranalol.
Cyclic AMP determination
Both AAV-β2AR/EGFP infected and mock-infected HEK
293 cells were cultured in DMEM with 10% FBS then in
serum-free media overnight. For cyclic AMP determina-
tion, cells were then treated either with vehicle or 10 µM
isoproterenol and the phosphodiesterase inhibitor, iso-
butylmethylxanthine (IBMX, 250 µM), for 10 minutes.
Cellular cyclic AMP levels were determined by radioim-
munoassay using the Biotrak CAMP Assay System (Amer-
sham Life Sciences, Arlington Heights, IL).
Fluorescence microscopy and receptor trafficking
For fluorescence microscopy, HEK 293 cells were cultured
in DMEM with 10% FBS at a density of 2.5 × 105 cells/well
on glass coverslips, infected with AAV-β2AR/EGFP and
treated on day 4 with vehicle or 10 µM isoproterenol for
24 hrs at 37°C. Cells were fixed with 1% paraformalde-
hyde at the designated time intervals. Efficiency of cell
infection was evaluated through imaging of green fluores-
cence as an indicator of EGFP expression. β2ARs were
detected with a rabbit polyclonal antibody specific to the
cytoplasmic tail of the human β2AR (1:500 dilution;
Bethyl Laboratories, Montgomery, TX) and Texas Red-
labeled (red fluorescence) goat anti-rabbit IgG antibody
(1:200 dilution; T2767; Molecular Probes, Eugene, OR) as
previously described [28]. Fluorescence imaging was then
performed with a Zeiss Axiovert digital deconvolution
microscope (Carl Zeiss, Inc., Thornwood, NY). For EGFP
expression, cells were visualized using epifluorescence
microscopy with a 100× oil objective. For β2AR detection,
images were collected using a 100× oil objective in Z-
stacks then digital deconvolution was performed using
AxioVision 3.1 (Carl Zeiss, Inc.). Images were then con-
verted to tagged-image files (tiff) for comparison.
Statistical analysis
Data are presented as the mean ± S.E.M. Comparisons
between groups were made by using one-way analysis of
variance (ANOVA) with Newman-Keuls post hoc testing.
The 0.05 level of probability was accepted as significant.
Computations were performed using the SigmaStat soft-
ware package (Jandel Scientific, San Rafael, CA).
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